TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $43.00

TG Therapeutics (NASDAQ:TGTX) had its target price upped by JPMorgan Chase & Co. from $30.00 to $43.00 in a research note issued to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on TGTX. HC Wainwright raised their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. TD Cowen initiated coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Up 2.2 %

TGTX opened at $35.00 on Monday. TG Therapeutics has a 12 month low of $12.32 and a 12 month high of $36.84. The company has a market cap of $5.45 billion, a PE ratio of -342.57 and a beta of 2.19. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a 50 day moving average of $26.00 and a 200 day moving average of $21.95.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the business earned $0.73 earnings per share. TG Therapeutics’s revenue was down 49.4% on a year-over-year basis. On average, sell-side analysts expect that TG Therapeutics will post 0.17 EPS for the current year.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently added to or reduced their stakes in TGTX. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the last quarter. Quarry LP boosted its holdings in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 503 shares during the period. Private Advisor Group LLC grew its position in TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. Finally, KBC Group NV boosted its stake in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,092 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.